Procter & Gamble Collaboration Identifies New Gene Targets
Procter & Gamble Pharmaceuticals (P&GP) announced that as part of their osteoporosis collaboration with Gene Logic, they have discovered 63 new gene targets. The targets are specifically regulated during osteoblastic cell development and may prove valuable in finding new agents that promote new bone formation. These new gene targets have been identified via functional genomics and bioinformatics and will be further assessed to determine their viability in bone drug development.
"This is very promising research which will keep us on the forefront of bone drug development, one of our therapeutic focus areas," said Gordon Hassing, vice president of R&D and Global Pharmaceuticals for P&G. P&G currently markets two osteoporosis drugs Actonel® (risedronate sodium tablets) and Didronel® (etidronate sodium).
P&G's collaboration with Gene Logic began in 1997 with a focus on heart failure. In 1998, the collaboration agreement was expanded to include osteoporosis-related genomic research. The agreement was further extended in 2000 when P&G became a subscriber to Gene Logic's GeneExpress Suite®.
Most read news
Other news from the department science

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Dow Completes First-Phase Expansion of Production Facility for LUMATION Light-Emitting Polymers (LEPs)
Yara to sell its minority position in Rossosh
LION bioscience Enters Cheminformatics Market with LeadNavigator(TM)
ORNL graphite foam technology licensed to LED North America
Abgenix And Sangstat Receive Orphan Drug Designation For Abx-Cbl For Treatment Of Acute Graft Versus Host Disease
